FGF21 Deficiency Worsens Retinal Inflammation and Damage in Mouse Models
Background
Fibroblast Growth Factor 21 (FGF21) is a crucial metabolic hormone known for its roles in glucose and lipid metabolism, and increasingly, its anti-inflammatory properties. The retina, a highly specialized neural tissue in the eye, is susceptible to various inflammatory conditions, such as uveitis and diabetic retinopathy, which can lead to vision loss. While FGF21's systemic anti-inflammatory effects are well-documented, the precise impact of endogenous FGF21 deficiency on the inflammatory microenvironment within the retina itself remained largely unexplored.
Study Design
Results
The study revealed that Fgf21 knockout mice exhibited significantly exacerbated retinal inflammation compared to wild-type controls following LPS challenge. At 48 hours post-LPS injection, Fgf21-/- mice showed a 2.8-fold increase in retinal TNF-α mRNA levels (p<0.001) and a 3.1-fold increase in IL-1β protein levels (p<0.001) compared to LPS-treated wild-type mice. Furthermore, CD45+ immune cell infiltration was elevated by 65% in the retinas of Fgf21-/- mice (p<0.01). Retinal thickness, measured by OCT, was 15% greater in Fgf21-/- mice at 72 hours (p<0.05), indicating more severe edema. The most significant finding was a 43% reduction in photoreceptor layer thickness in Fgf21-/- mice compared to wild-type controls following LPS challenge (p<0.001), highlighting increased retinal damage. Apoptosis markers like Caspase-3 activity were also 2.2-fold higher in Fgf21-/- retinas (p<0.001), confirming enhanced cell death.
Why It Matters
This study provides compelling evidence that endogenous FGF21 plays a critical protective role against retinal inflammation and damage. The findings suggest that maintaining adequate FGF21 levels could be a viable therapeutic strategy for various inflammatory retinal diseases, including uveitis, diabetic retinopathy, and potentially age-related macular degeneration. Targeting the FGF21 pathway, either through exogenous FGF21 administration or by enhancing endogenous production, could lead to novel clinical interventions to preserve vision. Future research should focus on validating these findings in humanized models and exploring specific FGF21 agonists in preclinical trials, paving the way for potential Phase II human trials.